Table 3. Potential anti-cancer activities of CPI-613 + gemcitabine combination in patients with stage IV pancreatic cancer, based on prolonged OS when compared to the results from Phase III trials of the current most effective chemotherapies in the clinic, FOLFIRINOX and Abraxane + Gemcitabine combination.

Patients				Stage of pancreatic cancer	ECOG at baseline	Chemotherapy prior to CPI-613	CPI-613		AE (severity gradeb) during study	Overall survival (months)c
Identity	Race	Gender	Agea				Dose (mg/m2)	# Of cycles
Low dose groups: median OS =5.3
001-106 R-A	Hispanic	Male	50	Stage IV	0	None	70	1	None	1.5
001-107 R-D	Caucasian	Male	62	Stage IV	0	Gemzar	105	1	None	9
High dose groups: OS =17.8
001-110 M-C	Caucasian	Female	64	Stage IV	0	None	150	1	Stomach ache (1); swelling around eyes and nose (1); vomiting (1)	7
001-111 B-M	Caucasian	Female	75	Stage IV	0	Gemzar; FOLFOX + Transferrin laced Oxaliplatin; 5-FU	150	1	Malaise (1); rash (2); rigors (1)	26
001-113 M-W	African-American	Female	76	Stage IV	0	None	190	2	Headache (1); elevated G-GTP (3)	~43 (still alive)
002-107 PAK	Caucasian	Male	64	Stage IV	1	Gemzar + Tarceva; Xeloda + investigational drug	320	2	Fatigue (1); weakness (1)	9.5

#, number; AE, adverse event; ECOG, Eastern Cooperative Oncology Group Performance Status; G-GTP, gamma-glutamyl transferase; ^a, age shown is the age at the start of the trial; ^b, severity grade was according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Event (CTCAE); ^c, survival was calculated from the start of the first chemotherapy for stage IV pancreatic cancer till death, which is the same criteria used in the FOLFIRINOX clinical trial (3) and the Abraxane + Gemcitabine combination clinical trials (4).